SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWellnex Life Regulatory News (WNX)

Share Price Information for Wellnex Life (WNX)

Share Price is delayed by 15 minutes
Get Live Data
4.25    0.00 (0.00%)
Bid:
4.00
Ask:
4.50
Spread: 0.50 (12.50%)
Market Cap: £3.10m
WNX Live PriceLast checked at - London Stock Exchange

Intraday Wellnex Life Share Chart

Market Update

16 Jan 2026 07:00

RNS Number : 1414P
Wellnex Life Limited
16 January 2026
 

 

 

 

ASX/AIM Announcement 16 January 2026

 

Market Update

 

Wellnex Life Limited (ASX/AIM:WNX) ("Wellnex Life" or the "Company") announces that Executive Chairman, Ash Vesali, is today providing the following update to shareholders, ahead of the Company's unaudited results for the 6 months to 31 December 2025.

 

Highlights:

· H1 FY26 EBITDA improved by $2.4 million versus prior comparative period ("PCP")

· Gross margin increased from 22.8% to 31.3%

· December 2025 EBITDA up $0.7 million year-on-year

· Group operating at breakeven as at Q2 FY26 close

· Pain Away quarterly sales (Q2 FY26) at $3.3 million with gross margin improved by 7.6%

· New distribution secured: Priceline for new SKUs, three major wholesaler NPD launches,

Dear Shareholder,

 

Wellnex enters H2 FY26 with improved stability and a clear turnaround trajectory. The Board and management have taken decisive action to simplify operations and instill cost discipline, with results now translating into measurable improvement.

Financial Performance

H1 FY26 EBITDA improved by $2.4 million versus the corresponding FY25 period, with Group gross margin increasing from 22.8% to 31.3%. December 2025 sustained the improvement first realised in November 2025, with EBITDA up $0.7 million year-on-year, driven by lower operating costs. The Group closed Q2 FY26 operating at breakeven, providing a solid platform entering H2 FY26.

Pain Away

Pain Away maintained market position while improving profitability in a competitive category, delivering $3.3 million in quarterly sales (Q2 FY26), with gross margin improving 7.6%. Heat patches grew 25% in Pharmacy versus 2% for the category In Australia, lifting market share to 18.5%, a 3-point gain year-on-year. Roll-ons grew 17% versus 0.3% for the topical pain sector, with our two SKUs ranked #1 and #3 ahead of a third roll-on launch by the Company planned in April 2026.

 

Distribution momentum continues, with Priceline launching five new SKUs [across Australia], and each of Wellnex's three major pharmacy wholesalers have confirmed four NPD launches. Furthermore, Costco Australia and Costco New Zealand will trial an exclusive heat patch in April 2026.

 

Contract Manufacturing

We are strengthening our planning discipline and are working with partners to implement a more productive and sustainable operating model focused on commercial value delivery.

As we move into 2026, Wellnex remains on course to deliver consistent performance with the goal of creating long-term shareholder value.

Happy New Year.

 

Ash Vesali

Executive Chairman

 

 

 

This ASX/AIM announcement has been authorised by the Board of Wellnex Life Limited (ASX/AIM:WNX).

For further information, please contact:

 

Wellnex Life Limited (ASX:WNX) Reach Markets

Ash Vesali T: 1300 805 941

Executive Chairman E: IR@reachmarkets.com.au

E: ash.v@wellnexlife.com.au

 

UK Investors

Strand Hanson (Financial & Nominated Advisor)

James Harris / Richard Johnson Tel: +44 (0) 20 7409 3494

Orana Corporate LLP (Joint Broker) swykeham@oranacorp.com

Sebastian Wykeham

 

S.P. Angel Corporate Finance LLP (Joint Broker) Tel: +44 (0)20 3470 0470

David Hignell / Vadim Alexandre

 

The information contained within this announcement is deemed by the Company to constitute inside information pursuant to article 7 of EU Regulation 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 as amended.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSFWESIEMSEIF
Date   Source Headline
12th Jun 20269:45 amRNSAppointment of Non-Executive Director
30th Apr 20267:30 amRNSQ3 FY26 Quarterly Update and Appendix 4C
23rd Apr 20267:00 amRNSExtension of Loan Repayment
21st Apr 20268:07 amRNSUpdate on loan repayment
7th Apr 202610:15 amRNSHolding(s) in Company
2nd Apr 20267:00 amRNSExtension of Haleon Licensing and Supply Agreement
27th Mar 20267:00 amRNSIssue of Shares
12th Mar 20267:00 amRNSBoard Changes
12th Mar 20267:00 amRNSBoard Changes
27th Feb 20267:30 amRNSHalf Yearly Report and Accounts
9th Feb 20267:00 amRNSCompany Update
29th Jan 20267:00 amRNSQ2 FY26 Quarterly Update and Appendix 4C
16th Jan 20267:00 amRNSMarket Update
15th Jan 20267:55 amRNSDirector/PDMR Shareholding
16th Dec 20257:30 amRNSTrading Update
27th Nov 20257:01 amRNSResults of AGM and Board Change
27th Nov 20257:00 amRNSWithdrawal of Resolution & Resignation of Director
27th Nov 20257:00 amRNSChair AGM Speech
10th Nov 20258:22 amRNSUpdate on Loan Repayment
3rd Nov 20257:00 amRNSUpdate on Loan Repayment
28th Oct 20257:18 amRNSNotice of Annual General Meeting
21st Oct 20257:00 amRNSResignation of CEO and Loan Repayment
20th Oct 20257:00 amRNSChairman’s letter - Shareholder Update
20th Oct 20257:00 amRNSQ1 FY26 Quarterly Report and Appendix 4C
3rd Oct 20257:12 amRNSIssue of Shares
1st Oct 20257:11 amRNSAppointment of Interim Executive Chairman
30th Sep 202510:31 amRNSAnnual Report for Year Ended 30 June 2025
22nd Sep 20257:00 amRNSCompany Update
19th Sep 20257:00 amRNSAppointment of Non-executive Chair
19th Sep 20257:00 amRNSExpanded Financing Facility
18th Sep 20257:00 amRNSAppointment of Storelink as NZ Distributor
15th Sep 20257:15 amRNSDirector Resignation
9th Sep 20257:25 amRNSAppointment of Non-Executive Chair
29th Aug 202510:12 amRNSAppendix 4E – Preliminary Final Report
15th Aug 20257:49 amRNSResignation of Joint CEO
1st Aug 20258:04 amRNSChange of Address
31st Jul 20257:33 amRNSQ4 FY25 Quarterly Report and Appendix 4C
2nd Jul 20257:13 amRNSDivestment of The Iron Company
19th May 20257:30 amRNSIssue of Shares
12th May 20252:00 pmRNSTrading Update
6th May 20257:09 amRNSBoard and Management Changes
14th Apr 20257:00 amRNSHolding(s) in Company
10th Apr 20257:00 amRNSAppointment of Powermed Plus as UK Distributor
8th Apr 20257:46 amRNSQ3 FY25 Quarterly Report and Appendix 4C
28th Mar 202510:30 amRNSHolding(s) in Company
27th Mar 20257:00 amRNSResult of WRAP Retail Offer
25th Mar 202510:30 amRNSIssue of Equity - Pain Away vendor shares
21st Mar 20257:00 amRNSAdmission to AIM and First Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.